The economic burden of carbapenem-resistant organisms (CROs) in critically ill patients is a growing concern in healthcare systems worldwide. This article explores the financial impact of CROs, focusing on their association with increased mortality, prolonged mechanical ventilation, extended ICU and hospital stays, and elevated medical costs. The study aims to quantify the economic burden associated with CRO colonization or infection in ICU patients using real-world data from two tertiary hospitals in Western China. The findings highlight the significant economic consequences of CROs, emphasizing the need for evidence-based infection control and resource planning strategies in high-risk care settings. The discussion also covers the importance of prudent antibiotic use, robust infection control measures, and effective diagnostic practices in mitigating the overall burden on the healthcare system. The study's implications underscore the importance of implementing early screening, stratified isolation, and antimicrobial stewardship interventions in high-risk ICU populations to prevent CRO infection and reduce the economic burden of infection.
